
From: Bumbray-Quarles, Devon (NIH/NIAID) [E]
Sent: Wednesday, April 20, 2016 12:05 PM
To: Stemmy, Erik (NIH/NIAID) [E] (b)(6)
Cc: Bumbray-Quarles, Devon (NIH/NIAID) [E] (b)(6)
Subject: Grant Number: 2R01AI089728 - 06 PI Name: Li, Fang

Hi Erik,

Have you reached out to the Grantee to receive a response for the following Summary Statement concerns? I didn't want to send a duplicate request and there wasn't anything submitted in the JIT.

BIOHAZARD COMMENT: There are concerns that recombinant coronaviruses altered to enhance proteolytic cleavage or binding of the human angiotensin converting enzyme 2 (ACE 2) receptor may have novel and unexpected virulence phenotypes. Therefore, biosafety level-3 (BSL-3) protections, training, and monitoring procedures should be considered unless otherwise indicated.

BUDGETARY OVERLAP: There is potential for budgetary overlap with the project R01AI110700 titled, "Mechanisms of MERS-CoV Entry, Cross-species Transmission and Pathogenesis" awarded to PI Ralph Baric (co-investigator on this proposal).

Thanks.

Sincerely,
Ms. Devon Bumbray-Quarles
Grants Management Specialist
Grants Management Program
DHHS, NIH, NIAID, GMP
5601 Fishers Lane, Room 4E28, MSC 9824
Bethesda, MD 20892-9824
Overnight Mail Only: Use Zip Code 20852
P: (b)(6)
F: 301.493.0597

(b)(6)



"Effective October 1, 2014, NIH closeout policy has changed (see [NOT-OD-14-084](#)). In order to avoid unilateral closeout, final reports must be submitted in a timely manner. Failure to submit accurate final reports could result in enforcement actions such as revisions to NOA funding levels, or delay in future funding."

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have